HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valisure’s Benzene Testing Challenged By PCPC; FDA Focus Should Be Raw Materials, Trade Group Says

Executive Summary

On roughly the 1-year anniversary of Valisure’s citizen petition to the FDA regarding benzene detected in body sprays, the Personal Care Products Council weighs in on the matter.

You may also be interested in...



Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules

 Plaintiffs in Multi-District Litigation didn’t provide scientific evidence of OTC heartburn drug Zantac increasing risk of cancer. Federal judge says plaintiffs' research showed “a lack of substantiation for analytical leaps” in alleging dangerously high levels of NDMA in ranitidine drugs.

Valisure Alerts US FDA To Benzene In Dry Shampoos, Says Any Detected Level Could Be ‘Unacceptable’

Valisure found 70% of 148 tested dry shampoo batches contained ‘quantifiable’ benzene. The US FDA advises a strict 2ppm limit when benzene’s use is unavoidable to produce a drug product with a “significant therapeutic advance.” In dry shampoos, “any significant detection of benzene could be deemed unacceptable,” Valisure suggests in its 31 October citizen petition to the agency.

Benzene Suits Against US Personal-Care Firms Appear Headed In One Direction: Settlement

The latest in litigation against Unilever, P&G, Beiersdorf and J&J alleging violations for selling personal-care products contaminated with benzene.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel